Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
Elias J JabbourFady Gh HaddadKoiji SasakiBing Z CarterYesid AlvaradoCedric NasnasLewis Fady NasrLucia MasarovaNaval G DaverNaveen PemmarajuNicholas James ShortJeffrey SkinnerTapan Mahendra KadiaGautam BorthakurGuillermo Garcia ManeroFarhad RavandiGhayas C IssaMichael AndreeffHagop M KantarjianPublished in: Cancer (2024)
Treatment with dasatinib and venetoclax was safe and effective in CML-CP. The cumulative response rates with the combination were similar to those with single-agent dasatinib. Further follow-up is needed to evaluate the rates of durable deep molecular response and treatment-free remission.